Advertisement

Ark Therapeutics primes market for likely financing update

Viral product-focused manufacturing services company Ark Therapeutics expects to update the market soon regarding possible financing, an announcement issued by the company on Monday disclosed.

Viral product-focused manufacturing services company Ark Therapeutics expects to update the market soon regarding possible financing, an announcement issued by the company on Monday disclosed.

The group announced that it was actively pursuing a number of options regarding the possible financing of the company and its business, including through an issue of equity on a non pre-emptive basis.

Advertisement - Article continues below

The company stated that there was "no guarantee" that the discussions would be successful yet also stated that it believed it would be in a position to "update the market shortly".

This follows a previous attempt by the group to gauge interest among shareholders over a potential equity fund-raising which it said had showed a level insufficient to justify continuing with the proposal.

Over the past year, the company said it had reduced its cost base, terminated all costly investment in early stage product development and re-structured its business to focus solely upon generating revenue from its viral development and manufacturing services based in Finland.

The group advised its shareholders that "in all likelihood, given the current share price and the expected level of investment being discussed, any equity financing proposal will be materially dilutive and subject to shareholder approval."

It added that the group's directors remained confident Ark has the potential to become a profitable, viral focused, contract development and manufacturing organisation.

In the meantime, and as previously announced, the company continues to explore opportunities to monetise its non-core assets, and is in discussions with a number of interested parties.

Ark Therapeutics has seven active clients and a number of further contracts in late stage negotiations.

Unaudited revenue for 2012 was up 300% to approximately £1.8m compared to 2011.

MF

Advertisement
Advertisement

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

An economics lesson from my barber
Inflation

An economics lesson from my barber

On reopening his shop after lockdown, Dominic Frisby’s barber doubled his prices. It’s all part of the post-Covid inflation process – and we’re going …
8 Jul 2020
What gold, bonds and tech stocks have in common
Stockmarkets

What gold, bonds and tech stocks have in common

"Risk off" or "safe haven" assets such as gold and government bonds have been doing well lately. But so have riskier tech stocks. That seems to defy c…
10 Jul 2020
Three ideas for Lloyds Bank's new boss
UK stockmarkets

Three ideas for Lloyds Bank's new boss

The Black Horse needs whipping into shape. A change at the top provides a great opportunity, says Matthew Lynn.
12 Jul 2020